These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28619123)

  • 1. CHD and respiratory syncytial virus: global expert exchange recommendations.
    Tulloh RMR; Medrano-Lopez C; Checchia PA; Stapper C; Sumitomo N; Gorenflo M; Jung Bae E; Juanico A; Gil-Jaurena JM; Wu MH; Farha T; Dodge-Khatami A; Tsang R; Notario G; Wegzyn C
    Cardiol Young; 2017 Oct; 27(8):1504-1521. PubMed ID: 28619123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.
    Warren A; Langley JM; Thomas W; Scott J
    Can J Cardiol; 2007 May; 23(6):463-6. PubMed ID: 17487291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease.
    Tulloh R; Marsh M; Blackburn M; Casey F; Lenney W; Weller P; Keeton BR;
    Cardiol Young; 2003 Oct; 13(5):420-3. PubMed ID: 14694935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palivizumab compliance in congenital heart disease patients: factors related to compliance and altered lower respiratory tract infection viruses after palivizumab prophylaxis.
    Sel K; Aypar E; Dönmez YN; Aliyev E; Aykan HH; Karagöz T; Alehan D
    Cardiol Young; 2020 Jun; 30(6):818-821. PubMed ID: 32425145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory syncytial virus hospitalisation trends in children with haemodynamically significant heart disease, 1997-2012.
    Chu PY; Hornik CP; Li JS; Campbell MJ; Hill KD
    Cardiol Young; 2017 Jan; 27(1):16-25. PubMed ID: 27161255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory syncytial virus prophylaxis in children with cardiac disease: a retrospective single-centre study.
    Butt M; Symington A; Janes M; Steele S; Elliott L; Chant-Gambacort C; Mondal T; Paes B
    Cardiol Young; 2014 Apr; 24(2):337-43. PubMed ID: 23628233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil.
    de Souza RP; Ribeiro ALR; de Menezes SAF; Machado LFA
    BMC Pediatr; 2019 Aug; 19(1):299. PubMed ID: 31462289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Respiratory Syncytial Virus Infection in Cyanotic Congenital Heart Disease in a Subtropical Area.
    Chiu SN; Shao PL; Chen HC; Lin MT; Huang LM; Kao FY; Huang SK; Wang JK; Wu MH
    J Pediatr; 2016 Apr; 171():25-30.e1. PubMed ID: 26822618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of a Novel Palivizumab Prophylaxis Protocol for Respiratory Syncytial Virus Infection in Congenital Heart Disease: A Multicenter Study.
    Chiu SN; Wang JN; Fu YC; Chung HT; Chang LY; Wu MH; Hua YC; Lin MT; Lu CW; Chen CA; Wu JM; Wang JK
    J Pediatr; 2018 Apr; 195():108-114.e1. PubMed ID: 29395174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RSV prophylaxis guideline changes and outcomes in children with congenital heart disease.
    Walpert AS; Thomas ID; Lowe MC; Seckeler MD
    Congenit Heart Dis; 2018 May; 13(3):428-431. PubMed ID: 29436781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors related to compliance with palivizumab prophylaxis for respiratory syncytial virus (RSV) infection - data from Poland.
    Borecka R; Lauterbach R; Helwich E
    Dev Period Med; 2016; 20(3):181-190. PubMed ID: 27941187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease.
    Cabalka AK
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S41-5. PubMed ID: 14730269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of palivizumab for the prevention of respiratory syncytial virus infections in children with congenital heart disease. Recommendations from the French Paediatric Cardiac Society].
    Chantepie A;
    Arch Pediatr; 2004 Nov; 11(11):1402-5. PubMed ID: 15519844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The European Forum for Clinical Management: prophylaxis against the respiratory syncytial virus in infants and young children with congenital cardiac disease.
    Tulloh RM; Feltes TF
    Cardiol Young; 2005 Jun; 15(3):274-8. PubMed ID: 15865829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE; Mahle WT
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005-2015).
    Li A; Wang DY; Lanctôt KL; Mitchell I; Paes BA;
    Pediatr Infect Dis J; 2017 May; 36(5):445-450. PubMed ID: 28403044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experience of palivizumab in prophylaxis of respiratory syncytial viral infection in premature children with bronchopulmonary dysplasia].
    Aliamovskaia GA; Keshinian ES
    Vestn Ross Akad Med Nauk; 2012; (12):30, 32-4. PubMed ID: 23530423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of palivizumab in infants and young children with severe respiratory disease: a Delphi study.
    Gaboli M; de la Cruz ÒA; de Agüero MI; Moreno-Galdó A; Pérez GP; de Querol MS
    Pediatr Pulmonol; 2014 May; 49(5):490-502. PubMed ID: 23775884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease.
    Duppenthaler A; Ammann RA; Gorgievski-Hrisoho M; Pfammatter JP; Aebi C
    Arch Dis Child; 2004 Oct; 89(10):961-5. PubMed ID: 15383442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating national guidelines for the prophylactic treatment of respiratory syncytial virus in children with congenital heart disease.
    Granbom E; Fernlund E; Sunnegårdh J; Lundell B; Naumburg E
    Acta Paediatr; 2014 Aug; 103(8):840-5. PubMed ID: 24724913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.